GlassScriptPhysician profile
Stewart C Vickrey
NPI 1982007431
$64,123.78
in general payments reported to CMS, 2019-2025
22 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25K · 2022: $18K · 2023: $19K · 2024: $2,168 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $2,076 · Travel and Lodging: $578 · Consulting Fee: $115 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,472.50 |
| Food and Beverage | $2,076.15 |
| Travel and Lodging | $577.71 |
| Consulting Fee | $115.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59,236.36 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $2,273.32 | 2021-2023 | Ingrezza |
| Corium, LLC | $946.53 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $397.88 | 2021-2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $321.47 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.61 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $179.62 | 2021-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $80.31 | 2021-2022 | |
| Lundbeck LLC | $76.02 | 2021 | |
| Sunovion Pharmaceuticals INC. | $73.87 | 2021 | |
| Novo Nordisk INC | $71.46 | 2022-2023 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $64.16 | 2023 | Auvelity |
| Glaxosmithkline, LLC. | $33.21 | 2023-2024 | Bexsero |
| Arbor Pharmaceuticals, INC. | $28.87 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.44 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $25.34 | 2024 | Urolift |
| Otsuka America Pharmaceutical, INC. | $22.52 | 2022 | |
| Hologic Sales and Service, LLC | $17.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.13 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.90 | 2022 | |
| Lilly USA, LLC | $13.93 | 2023 | Jardiance |
| Bausch Health US, LLC | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stewart Vickrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.